0000920465-20-000156.txt : 20201105 0000920465-20-000156.hdr.sgml : 20201105 20201105165954 ACCESSION NUMBER: 0000920465-20-000156 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201030 FILED AS OF DATE: 20201105 DATE AS OF CHANGE: 20201105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hearne Michael S CENTRAL INDEX KEY: 0001759910 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36282 FILM NUMBER: 201291374 MAIL ADDRESS: STREET 1: 4747 EXECUTIVE DRIVE STREET 2: SUITE 210 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LA JOLLA PHARMACEUTICAL CO CENTRAL INDEX KEY: 0000920465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330361285 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4747 EXECUTIVE DRIVE, SUITE 240 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-207-4264 MAIL ADDRESS: STREET 1: 4747 EXECUTIVE DRIVE, SUITE 240 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 wf-form4_160461358133519.xml FORM 4 X0306 4 2020-10-30 0 0000920465 LA JOLLA PHARMACEUTICAL CO LJPC 0001759910 Hearne Michael S C/O LA JOLLA PHARMACEUTICAL COMPANY 4747 EXECUTIVE DRIVE, SUITE 240 SAN DIEGO CA 92121 0 1 0 0 Chief Financial Officer Common Stock 2020-10-30 4 A 0 196 2.89 A 365 D Common Stock 9405490 I By LP Employee Stock Option (Right to Buy) 3.4 2020-10-30 4 A 0 196 0 A 2030-10-30 Common Stock 196.0 196 D These shares were acquired on 10/30/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Tang Capital Management, LLC ("TCM") is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as the Chief Financial Officer of TCM. Mr. Hearne has a pecuniary interest in a portion of the shares beneficially held by TCP. The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years. /s/ Michael Hearne 2020-11-05